The success of Viagra initially sparked a period of growth for major pharmaceutical companies, but recent shifts present a uncertain picture for those considering a stake. Generic versions are eroding revenue, and continued legal battles add more difficulty to the landscape. While certain companies could still see gains from related products, the b